Control of Peroxisome Proliferator-Activated Receptor Fate by the UbiquitinProteasome System

Peroxisome proliferator-activated receptor (PPAR) α, γ, and δ belong to the nuclear hormone receptor superfamily of ligand-activated transcription factors. PPARs regulate metabolic, developmental, and differentiation pathways and play important roles in human diseases, such as diabetes, atherosclerosis, cancer, and chronic inflammation. PPARs are the targets of drugs of widespread clinical use and represent promising targets for discovery of new therapeutics. The interaction of PPARs with the ubiquitin-proteasome system (UPS) has been the subject of limited investigation. The UPS plays an important role in regulating the levels and modulating ligand-dependent and-independent activity of nuclear receptors. This review highlights the current knowledge regarding the interactions of the UPS with PPARs and focuses on the differential regulation of the level and activity of the PPAR isotypes by the UPS in response to selective ligands. Understanding the connections between the UPS and PPARs can provide insights in the actions of existing drugs and raise the possibilities for development of more effective PPAR-based therapeutics.

[1]  Philippe Lefebvre,et al.  Sorting out the roles of PPARα in energy metabolism and vascular homeostasis , 2006 .

[2]  R. Evans,et al.  PPARδ: a dagger in the heart of the metabolic syndrome , 2006 .

[3]  W. Wahli,et al.  Involvement of PPAR nuclear receptors in tissue injury and wound repair. , 2006, The Journal of clinical investigation.

[4]  S. O’Rahilly,et al.  PPARγ and human metabolic disease , 2006 .

[5]  T. Gray,et al.  Both PPARγ and PPARδ influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line , 2005, Oncogene.

[6]  C. Rochette-Egly.  Dynamic Combinatorial Networks in Nuclear Receptor-mediated Transcription* , 2005, Journal of Biological Chemistry.

[7]  B. O’Malley,et al.  Inhibition of the 26S proteasome blocks progesterone receptor-dependent transcription through failed recruitment of RNA polymerase II , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  Vincent Laudet,et al.  Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.

[9]  C. Glass,et al.  A Corepressor/Coactivator Exchange Complex Required for Transcriptional Activation by Nuclear Receptors and Other Regulated Transcription Factors , 2004, Cell.

[10]  R. Deshaies,et al.  Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation , 2003, Nature Cell Biology.

[11]  M. Muratani,et al.  How the ubiquitin–proteasome system controls transcription , 2003, Nature Reviews Molecular Cell Biology.

[12]  B. Staels,et al.  Peroxisome Proliferator-activated Receptor α (PPARα) Turnover by the Ubiquitin-Proteasome System Controls the Ligand-induced Expression Level of Its Target Genes* , 2002, The Journal of Biological Chemistry.

[13]  B. Deroo,et al.  Proteasome Inhibitors Reduce Luciferase and β-Galactosidase Activity in Tissue Culture Cells* , 2002, The Journal of Biological Chemistry.

[14]  H. Sheng,et al.  Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. , 2002, Cancer research.

[15]  P. Sharp,et al.  Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T. Tanabe,et al.  Prostacyclin-dependent Apoptosis Mediated by PPARδ* , 2001, The Journal of Biological Chemistry.

[17]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[18]  T. Tsukamoto,et al.  Stabilization of Peroxisome Proliferator-Activated Receptor α by the Ligand☆ , 2001 .

[19]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[20]  Z. Nawaz,et al.  Importance of the regulation of nuclear receptor degradation. , 2001, Frontiers in bioscience : a journal and virtual library.

[21]  Á. Pascual,et al.  Nuclear hormone receptors and gene expression. , 2001, Physiological reviews.

[22]  Bert Vogelstein,et al.  Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Willson,et al.  Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Chambon,et al.  Dimerization with Retinoid X Receptors and Phosphorylation Modulate the Retinoic Acid-induced Degradation of Retinoic Acid Receptors α and γ through the Ubiquitin-Proteasome Pathway* , 2000, The Journal of Biological Chemistry.

[25]  B. Spiegelman,et al.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Spiegelman,et al.  PAX8-PPARγ1 Fusion in Oncogene Human Thyroid Carcinoma , 2000 .

[27]  C. J. Chen,et al.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. , 2000, Science.

[28]  Li Zhao,et al.  Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Dittmar,et al.  Cell Cycle–Regulated Modification of the Ribosome by a Variant Multiubiquitin Chain , 2000, Cell.

[30]  B. Spiegelman,et al.  Degradation of the Peroxisome Proliferator-activated Receptor γ Is Linked to Ligand-dependent Activation* , 2000, The Journal of Biological Chemistry.

[31]  B. O’Malley,et al.  The 26S Proteasome Is Required for Estrogen Receptor-α and Coactivator Turnover and for Efficient Estrogen Receptor-α Transactivation , 2000 .

[32]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[33]  A. Ciechanover,et al.  Ubiquitin‐mediated proteolysis: biological regulation via destruction , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[34]  M. Koken,et al.  Retinoic Acid Induces Proteasome-Dependent Degradation of Retinoic Acid Receptor α (RARα) and Oncogenic RARα Fusion Proteins , 1999 .

[35]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[36]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[37]  J. Voorhees,et al.  1,25-Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin. , 1999, Molecular endocrinology.

[38]  Satoshi Tanaka,et al.  PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .

[39]  E. Alarid,et al.  Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. , 1999, Molecular endocrinology.

[40]  P. Leedman,et al.  Differential Posttranscriptional Regulation of Androgen Receptor Gene Expression by Androgen in Prostate and Breast Cancer Cells , 1999 .

[41]  B. Spiegelman,et al.  Loss-of-Function Mutations in PPARγ Associated with Human Colon Cancer , 1999 .

[42]  S. Jentsch,et al.  A Novel Ubiquitination Factor, E4, Is Involved in Multiubiquitin Chain Assembly , 1999, Cell.

[43]  M. Tsai,et al.  The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily , 1999, Molecular and Cellular Biology.

[44]  P. Tuohimaa,et al.  Evidence for enhanced ubiquitin-mediated proteolysis of the chicken progesterone receptor by progesterone. , 1998, Life sciences.

[45]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[46]  P. Raskin,et al.  Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. , 1998, The New England journal of medicine.

[47]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[48]  C. Pickart.  Targeting of substrates to the 26S proteasome , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  J. Cidlowski,et al.  Mouse Glucocorticoid Receptor Phosphorylation Status Influences Multiple Functions of the Receptor Protein* , 1997, The Journal of Biological Chemistry.

[50]  B. Spiegelman,et al.  Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[51]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[52]  K. Umesono,et al.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[53]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[54]  B. Katzenellenbogen,et al.  Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. , 1988, Molecular endocrinology.

[55]  R. Baum,et al.  Isolation and characterization of protein A24, a "histone-like" non-histone chromosomal protein. , 1975, The Journal of biological chemistry.

[56]  Christopher K. Glass,et al.  Combinatorial roles of nuclear receptors in inflammation and immunity , 2006, Nature Reviews Immunology.

[57]  Béatrice Desvergne,et al.  Peroxisome-proliferator-activated receptors and cancers: complex stories , 2004, Nature Reviews Cancer.

[58]  B. Staels,et al.  Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. , 2002, The Journal of biological chemistry.

[59]  K. Kinzler,et al.  Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Fabienne,et al.  Differential Expression of Peroxisome Proliferator-Activated Receptors (PPARs): Tissue Distribution of PPAR-a, $3, and -y in the Adult Rat* , 2001 .

[61]  K. Kinzler,et al.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. , 1999, Cell.

[62]  J. Auwerx,et al.  Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice , 1998, Nature Medicine.

[63]  L. Hicke,et al.  A function for monoubiquitination in the internalization of a G protein-coupled receptor. , 1998, Molecular cell.

[64]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[65]  K. Yu.  Conjugation and deconjugation of ubiquitin regulating the destiny of proteins , 2022 .